Lilly's EloraTZP Delivers 23.3% Weight Loss in Phase 2b, Advancing to Phase 3

What Happened

Eli Lilly has introduced a new name into the weight-loss lexicon: EloraTZP, a combination of the selective amylin agonist eloralintide and Lilly's dual GIP/GLP-1 receptor agonist tirzepatide. Presented at the European Association for the Study of Diabetes (EASD) annual meeting in Milan, the Phase 2b trial enrolled 367 adults with obesity or overweight and type 2 diabetes.

At 48 weeks, the highest combination dose produced average weight loss of 23.3%, compared with 14.8% for tirzepatide alone and 3% for placebo. Eloralintide on its own cut weight by up to an average of 12.3% in the same trial. Blood-sugar control improved in parallel: A1C, a measure of average blood glucose over the preceding two to three months, fell by an average of 2.9 percentage points on the top combination dose, versus 2.4 for tirzepatide alone and 0.3 for placebo. Every dose combination tested met the trial's primary and secondary endpoints, and Lilly said it will launch Phase 3 trials before the end of the year.

Who Is Affected

• Adults with obesity and type 2 diabetes — the population studied, and the group for whom next-generation combination therapy is arriving fastest.
• The amylin class — the data position amylin agonism as the most credible partner to incretin therapy, a race that also includes Novo Nordisk's CagriSema.
• Peptide researchers — Lilly's chief scientific officer has described eloralintide as the first agonist preferential and specific for amylin rather than calcitonin receptors, a selectivity problem that has dogged the class for years.

Timeline

• November 2025 — eloralintide's Phase 2 monotherapy readout: up to 20.1% weight loss at 48 weeks, exceeding analyst expectations.
• September 2026 — Novo Nordisk reports that CagriSema beat tirzepatide head-to-head in adults with type 2 diabetes, 12.4% weight loss versus 9.1% at week 60.
• September 30, 2026 — EloraTZP Phase 2b data presented at EASD in Milan.
• Q4 2026 — Phase 3 launch planned for the combination; a separate Phase 3 monotherapy trial in obesity without diabetes is ongoing.

What This Means for Researchers

Two findings deserve scrutiny beyond the headline. First, the efficacy numbers use the efficacy estimand — they reflect outcomes for participants regardless of discontinuation, a framing choice that flatters the topline when tolerability is rocky. Second, tolerability is the open question: discontinuation due to adverse events ranged from 10.8% to 27% across combination dose arms, versus 2.9% for tirzepatide alone. Lilly executives attribute this to the short 48-week design and the simultaneous titration of two drugs, and say the Phase 3 study will run longer with an optimized escalation schedule.

The strategic lesson is pharmacological: pairing amylin agonism with incretin agonism produced effects neither class achieves alone — evidence that rational peptide combinations, rather than single-molecule escalation, may be the next frontier of metabolic drug development.

How to Verify Your Peptides

Amylin-class compounds are already circulating in the research-chemical market, well ahead of any approval. Treat any unregulated source as unverified until tested:

• How third-party lab testing works
• HPLC versus LC-MS: what each method reveals
• Identity, purity and fill-weight reports explained

Safe Alternatives

• Work with documented compounds in the research-grade peptide landscape
• Compare sources in the vendor directory

Sources

Data presented at the European Association for the Study of Diabetes 2026 annual meeting; industry announcements.